Eli Lilly announced the acquisition of three vaccine developers in separate deals totaling up to $3.83 billion, marking a deliberate push into the infectious disease space. The targets bring vaccines in development for shingles, bacterial pathogens, and the Epstein-Barr virus. The move represents a meaningful strategic pivot for a company best known for its diabetes and obesity drug portfolio.
This diversifies Lilly's revenue pipeline beyond GLP-1 drugs like Mounjaro, reducing single-franchise risk that has weighed on how investors value the stock. Vaccine markets — particularly shingles, where GSK's Shingrix generates over $4 billion annually — are large and defensible. Investors in LLY should watch whether these assets can realistically compete with entrenched players; the upside is real but so is the execution risk on three simultaneous integrations.
Q2 2025 Lilly earnings call (expected late July): management will likely address integration timelines and milestone payment structures. FDA advisory committee calendar: watch for any shingles or EBV vaccine-related meetings. GSK and Pfizer vaccine pipeline updates will signal how competitive the landscape is becoming.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief